Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 2 8Phase 1/2 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 42Specimen Handling 38Magnetic Resonance Spectroscopy 30Carboplatin 30Cyclophosphamide 27Biopsy 25Nivolumab 23Dexamethasone 22fludarabine 21Gemcitabine 19Bevacizumab 15Paclitaxel 14Temozolomide 13Pemetrexed 13Docetaxel 13Cisplatin 13atezolizumab 12Ipilimumab 12Rituximab 11venetoclax 10Prednisone 10Lenalidomide 9Injections 9Fulvestrant 9lenvatinib 8X-Rays 8Vincristine 8Trastuzumab 8Oxaliplatin 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × decitabine and cedazuridine drug combination × 30 days × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT04774393 2026-05-20

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05360160 2026-05-20

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
43 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡